FY23 DBH Medically Monitored Intensive Withdrawal Management Services (MMIWM)

The District of Columbia's Department of Behavioral Health (DBH) is seeking proposals for FY23 Medically Monitored Intensive Withdrawal Management Services (MMIWM), a critical healthcare procurement focused on providing specialized substance abuse treatment and withdrawal management. The contract aims to deliver comprehensive medical support for individuals experiencing complex substance withdrawal symptoms, requiring intensive clinical monitoring and intervention. Potential vendors must demonstrate expertise in addiction medicine, medical stabilization, and patient-centered withdrawal management protocols. The solicitation requires providers to offer comprehensive clinical services, including 24/7 medical supervision, individualized treatment planning, and integrated behavioral health support. Proposals are due on March 28, 2023, with the procurement process initiated on March 6, 2023. Vendors must submit detailed documentation demonstrating clinical capabilities, staff qualifications, treatment methodologies, and compliance with District of Columbia healthcare regulations. Evaluation criteria will likely include clinical expertise, staff credentials, treatment success rates, operational infrastructure, and cost-effectiveness of proposed services.

The procurement appears designed to support disadvantaged and underserved populations, potentially with set-aside considerations for local or minority-owned healthcare providers. While specific set-aside designations are not explicitly detailed in the provided information, the District of Columbia often prioritizes local and certified business enterprises in its contracting processes. The contract likely targets providers with established medical infrastructure capable of integrating with existing District behavioral health systems and electronic health record platforms. Although exact budget ranges are not specified, similar medically intensive withdrawal management contracts in urban jurisdictions typically range between $500,000 to $2 million annually. Vendors must possess appropriate licensing, accreditation from recognized healthcare bodies, and demonstrate capacity to serve diverse patient populations with complex substance abuse and withdrawal management needs. Potential respondents should carefully review all requirements and be prepared to provide comprehensive clinical and operational documentation demonstrating their capability to deliver high-quality, patient-centered withdrawal management services.